| Host: |
HEK293 |
| Note: |
STRICTLY FOR FURTHER RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
| Short Description: |
Recombinant-Human Kallikrein-6-protein was developed from hek293. For use in research applications. |
| Conjugation: |
Unconjugated |
| Formulation: |
Lyophilised from 0.2 Mu m filtered PBS solution, pH7.2, 5% Trehalose. |
| Dilution Range: |
Spin the vial and reconstite in distilled water to a concentration not less than 0.1 mg/mL. This can then be diluted into other buffers. |
| Storage Instruction: |
Can be stored in working aliquots at 2°C-8°C C for one month, or at-20°C to-70°C for 1 year. Avoid repeated freeze/thaw cycles. NA |
| Endotoxin: |
Endotoxin content was assayed using a LAL gel clot method. Endotoxin level was found to be less than 0.1 ng/µg (1EU/µg). NA |
| Immunoreactivity: |
The activity was tested by the ability to cleave a fluorogenic substrate Boc-QARAMC.The specific activity was measured to be 250 pmole/ug/min NA |
| Gene Symbol: |
KLK6 |
| Gene ID: |
5653 |
| Uniprot ID: |
KLK6_HUMAN |
| Immunogen Region: |
GLU17-LYS244 |
| Immunogen: |
Optimized DNA sequence encoding Human Kallikrein-6-KLK6 (GLU17-LYS244 ) preprotein including a C-terminal His tag was expressed in HEK293 cells. NA |
| Tissue Specificity | In fluids, highest levels found in milk of lactating women followed by cerebrospinal fluid, nipple aspirate fluid and breast cyst fluid. Also found in serum, seminal plasma and some amniotic fluids and breast tumor cytosolic extracts. Not detected in urine. At the tissue level, highest concentrations found in glandular tissues such as salivary glands followed by lung, colon, fallopian tube, placenta, breast, pituitary and kidney. Not detected in skin, spleen, bone, thyroid, heart, ureter, liver, muscle, endometrium, testis, pancreas, seminal vesicle, ovary, adrenals and prostate. In brain, detected in gray matter neurons (at protein level). Colocalizes with pathological inclusions such as Lewy bodies and glial cytoplasmic inclusions. Overexpressed in primary breast tumors but not expressed in metastatic tumors. |
| Post Translational Modifications | Inactivated by autolytic cleavage after Arg-80. |
| Function | Serine protease which exhibits a preference for Arg over Lys in the substrate P1 position and for Ser or Pro in the P2 position. Shows activity against amyloid precursor protein, myelin basic protein, gelatin, casein and extracellular matrix proteins such as fibronectin, laminin, vitronectin and collagen. Degrades alpha-synuclein and prevents its polymerization, indicating that it may be involved in the pathogenesis of Parkinson disease and other synucleinopathies. May be involved in regulation of axon outgrowth following spinal cord injury. Tumor cells treated with a neutralizing KLK6 antibody migrate less than control cells, suggesting a role in invasion and metastasis. |
| Protein Name | Kallikrein-6NeurosinProtease MSp59Serine Protease 18Serine Protease 9Zyme |
| Cellular Localisation | SecretedNucleusNucleolusCytoplasmMitochondrionMicrosomeIn BrainDetected In The Nucleus Of Glial Cells And In The Nucleus And Cytoplasm Of NeuronsDetected In The Mitochondrial And Microsomal Fractions Of Hek-293 Cells And Released Into The Cytoplasm Following Cell Stress |
| Alternative Protein Names | Kallikrein-6 proteinNeurosin proteinProtease M proteinSp59 proteinSerine Protease 18 proteinSerine Protease 9 proteinZyme proteinKLK6 proteinPRSS18 proteinPRSS9 protein |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance
